The overall goal of this project is to define the epigenetic and transcriptional mechanisms underlying cellular reprogramming, a process by which cells switch from a hepatocyte program to a biliary program in vivo. In the liver, correct spatial organization is essential for function, and disruption of normal architecture (by fibrosis) underlies most cases of severe chronic liver disease. The configuration of the biliary tree is of particular importance, and bile duct dysfunction (from obstruction, destruction, or congenital malformation) is a significant cause of liver-associated morbidity and mortality. A clearer picture of how bile ducts are made and remodeled during injury and regeneration will thus have a major impact on our understanding of disease pathogenesis, informing novel strategies for regenerative therapies. In the last grant period, we made several important discoveries related to biliary development, adult cell plasticity, and liver regeneration. Among these was the finding that the Notch pathway - a conserved signaling module known to be important in bile duct development - acts by coordinating biliary differentiation with morphogenesis through a novel tubulogenesis mechanism. Furthermore, we found that newborn and adult hepatocytes retain significant cellular plasticity, exhibiting the ability to undergo in vivo reprogramming (also termed metaplasia or trans-differentiation) to biliary epithelial cells (BECs). Such reprogramming occurs as part of the liver's physiological response to injury and requires Notch signaling. Moreover, Notch itself can drive reprogramming by pushing cells through a stepwise cascade of transcriptional, morphological and functional changes. These discoveries lay the groundwork for the current proposal, with the objective of defining the mechanisms underlying cellular reprogramming in vivo and exploiting these insights for the treatment of cholestatic disease in humans. These objectives will be achieved through the following two interrelated Specific Aims:
Specific Aim 1 : Determine the molecular mechanisms of hepatocyte-to-biliary reprogramming in vivo.
Specific Aim 2 : Examine the function and therapeutic potential of biliary reprogramming in vivo. These efforts will provide an unprecedented window into the transcriptional, functional, and epigenetic changes that occur during a change in cell identity in vivo. Importantly, because biliary reprogramming is part of the liver's normal injury response, these insights will have direc physiological relevance. Finally, by using both established mouse models and an innovative human transplantation system in which reprogramming occurs, these studies may provide mechanistic insights that can be used to tip the balance between hepatocytes and BECs, leading to novel treatments for liver disease.

Public Health Relevance

We have previously shown that under physiological injury conditions, hepatocytes undergo a process of trans-differentiation (or 'reprogramming') to become biliary epithelial cells (BECs). The overall goal of this project is to define the molecular mechanisms underlying reprogramming in both mice and humans, with a focus on global changes in transcriptional networks and chromatin structure. We anticipate that these mechanistic studies will facilitate the development of agents that can tip the balance between these two cell types, leading to novel treatments for liver disease, especially bile duct paucity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK083355-10
Application #
9856363
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Sherker, Averell H
Project Start
2009-07-01
Project End
2021-01-31
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
10
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ko, Jina; Bhagwat, Neha; Yee, Stephanie S et al. (2017) A magnetic micropore chip for rapid (<1 hour) unbiased circulating tumor cell isolation and in situ RNA analysis. Lab Chip 17:3086-3096
Li, Bin; Dorrell, Craig; Canaday, Pamela S et al. (2017) Adult Mouse Liver Contains Two Distinct Populations of Cholangiocytes. Stem Cell Reports 9:478-489
Spaeth, Jason M; Hunter, Chad S; Bonatakis, Lauren et al. (2015) The FOXP1, FOXP2 and FOXP4 transcription factors are required for islet alpha cell proliferation and function in mice. Diabetologia 58:1836-44
Shen, Zhewei; Stanger, Ben Z (2015) YAP regulates S-phase entry in endothelial cells. PLoS One 10:e0117522
Stanger, Ben Z (2015) Cellular homeostasis and repair in the mammalian liver. Annu Rev Physiol 77:179-200
Chen, Yi-Ju; Finkbeiner, Stacy R; Weinblatt, Daniel et al. (2014) De novo formation of insulin-producing ""neo-? cell islets"" from intestinal crypts. Cell Rep 6:1046-1058
Yimlamai, Dean; Christodoulou, Constantina; Galli, Giorgio G et al. (2014) Hippo pathway activity influences liver cell fate. Cell 157:1324-38
Gao, Tao; McKenna, Brian; Li, Changhong et al. (2014) Pdx1 maintains ? cell identity and function by repressing an ? cell program. Cell Metab 19:259-71
Wang, Ting; Yanger, Kilangsungla; Stanger, Ben Z et al. (2014) Cytokinesis defines a spatial landmark for hepatocyte polarization and apical lumen formation. J Cell Sci 127:2483-92
Rhim, Andrew D; Oberstein, Paul E; Thomas, Dafydd H et al. (2014) Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25:735-47

Showing the most recent 10 out of 24 publications